KalVista Pharmaceuticals (KALV) Insider Trading & Ownership $13.56 +0.05 (+0.33%) As of 10:05 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KalVista Pharmaceuticals (NASDAQ:KALV) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage4.30%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$2.40MNumber OfInsiders Selling(Last 12 Months)3Amount OfInsider Selling(Last 12 Months)$1.56M Get KALV Insider Trade Alerts Want to know when executives and insiders are buying or selling KalVista Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KALV Insider Buying and Selling by Quarter KalVista Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/25/2025Nicole SweenyInsiderSell1,480$13.42$19,861.60 8/25/2025Paul K AudhyaInsiderSell2,336$13.42$31,349.12 8/22/2025Benjamin L PalleikoCEOSell10,940$13.22$144,626.80 8/22/2025Nicole SweenyInsiderSell1,864$13.22$24,642.08 8/22/2025Paul K AudhyaInsiderSell2,942$13.22$38,893.24 7/9/2025Benjamin L PalleikoCEOSell32,979$15.69$517,440.51 6/9/2025Benjamin L PalleikoCEOSell7,169$14.50$103,950.50 5/23/2025Paul K AudhyaInsiderSell2,146$11.31$24,271.26 5/19/2025Benjamin L PalleikoCEOSell3,808$11.84$45,086.72 5/19/2025Paul K AudhyaInsiderSell2,776$11.84$32,867.84 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 4/9/2025Venrock Healthcare Capital ParMajor ShareholderBuy25,000$9.42$235,500.00 3/7/2025Benjamin L PalleikoCEOSell6,669$11.97$79,827.93 2/24/2025Paul K AudhyaInsiderSell2,394$10.02$23,987.88 2/18/2025Benjamin L PalleikoCEOSell5,104$9.82$50,121.28 2/18/2025Paul K AudhyaInsiderSell3,125$9.82$30,687.50 2/12/2025Venrock Healthcare Capital ParMajor ShareholderBuy100,000$9.23$923,000.00 2/10/2025Venrock Healthcare Capital ParMajor ShareholderBuy4,137$9.14$37,812.18 2/7/2025Venrock Healthcare Capital ParMajor ShareholderBuy73,649$9.29$684,199.21 2/3/2025Venrock Healthcare Capital ParMajor ShareholderBuy14,562$9.22$134,261.64 1/30/2025Venrock Healthcare Capital ParMajor ShareholderBuy43,707$8.76$382,873.32 12/9/2024Benjamin L PalleikoCEOSell7,627$9.75$74,363.25 11/26/2024Paul K AudhyaInsiderSell2,187$9.87$21,585.69 11/18/2024Benjamin L PalleikoCEOSell14,400$9.26$133,344.00 11/18/2024Paul K AudhyaInsiderSell8,077$9.26$74,793.02 9/9/2024Benjamin L PalleikoCEOSell7,352$12.19$89,620.88 (Data available from 1/1/2013 forward) KALV Insider Trading Activity - Frequently Asked Questions Who is on KalVista Pharmaceuticals' Insider Roster? The list of insiders at KalVista Pharmaceuticals includes Albert Cha, Benjamin L Palleiko, Christopher Yea, Edward P Feener, Nicole Sweeny, Paul K Audhya, Thomas Andrew Crockett, and Venrock Healthcare Capital Par. Learn more on insiders at KALV. What percentage of KalVista Pharmaceuticals stock is owned by insiders? 4.30% of KalVista Pharmaceuticals stock is owned by insiders. Learn more on KALV's insider holdings. Which KalVista Pharmaceuticals insiders have been buying company stock? The following insider purchased KALV shares in the last 24 months: Venrock Healthcare Capital Par ($8,203,926.65). How much insider buying is happening at KalVista Pharmaceuticals? Insiders have purchased a total of 709,577 KALV shares in the last 24 months for a total of $8,203,926.65 bought. Which KalVista Pharmaceuticals insiders have been selling company stock? The following insiders have sold KALV shares in the last 24 months: Albert Cha ($189,000.00), Benjamin L Palleiko ($2,075,149.53), Christopher Yea ($85,295.02), Edward P Feener ($1,012,679.62), Nicole Sweeny ($44,503.68), Paul K Audhya ($304,909.55), and Thomas Andrew Crockett ($711,769.68). How much insider selling is happening at KalVista Pharmaceuticals? Insiders have sold a total of 350,217 KalVista Pharmaceuticals shares in the last 24 months for a total of $4,423,307.08 sold. KalVista Pharmaceuticals Key ExecutivesMr. Benjamin L. Palleiko (Age 58)CEO & Director Compensation: $983.07k5 recent tradesDr. Christopher M. Yea Ph.D. (Age 60)Chief Development Officer Compensation: $708.53kDr. Paul K. Audhya M.B.A. (Age 51)M.D., Chief Medical Officer Compensation: $736.82kMr. Brian Piekos (Age 49)Chief Financial Officer Mr. Ryan BakerHead of Investor RelationsMr. Brian Krex J.D. (Age 56)General Counsel Jarrod AldomVice President of Corporate CommunicationsMs. Rachel M. MortenSenior Vice President of Regulatory Affairs & QADr. Michael D. Smith Pharm.D. (Age 44)Senior Vice President of Development Ms. Nicole Sweeny (Age 48)Chief Commercial Officer 2 recent trades More Insider Trading Tools from MarketBeat Related Companies RXRX Insider Selling CPRX Insider Selling KNSA Insider Selling OGN Insider Selling CNTA Insider Selling IBRX Insider Selling TARS Insider Selling OCUL Insider Selling AGIO Insider Selling DNLI Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Costco Faces Downgrades, Death Cross, Insider SellingReynolds Consumer Products Stock Price: Insiders Signal a BottomBuy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksInsiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift45 Stocks Insiders Are Selling That Analysts Say Buy This page (NASDAQ:KALV) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access